Trial Profile

A Phase I/IIa, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-8263 in Adult Patients With Advanced Malignant Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 22 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs JAB-8263 (Primary)
Indications Acute myeloid leukaemia; Haematological malignancies; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Prostate cancer; Small cell lung cancer; Solid tumours
Focus Adverse reactions; First in man
Sponsors Jacobio Pharmaceuticals

09 Jan 2026 Planned End Date changed from 1 Sep 2024 to 1 Jul 2028.
09 Jan 2026 Planned primary completion date changed from 1 Jan 2024 to 1 Jan 2028.
03 Jul 2025 According to a Jacobio Pharmaceuticals media release, data from this study presented at the 2024 American Society of Hematology (ASH) Annual Meeting showed that JAB-8263 demonstrated good tolerability.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com